The treatment of established veno-occlusive disease (VOD) of the liver with tissue plasminogen activator (tPA) has been disappointing. In attempts to improve upon these results we identified a subgroup of patients with consistently elevated bilirubin levels who did not meet conventional criteria for VOD (Susp VOD) but who had a significant risk of later developing clinical VOD. In January 1994 we began to treat patients who developed Susp VOD with tPA rather than waiting until they developed clinical VOD. We now report on the results of the first 37 patients who ultimately developed clinical VOD and received tPA therapy prior to Susp VOD, or at the time they had established VOD. Significant bleeding complications occurred in 13 (35%) patients but resolved with discontinuation of therapy in all but one. We found that patients treated early in the course of hepatotoxicity prior to the development of overt VOD had a significantly higher response rate and 100 day survival than patients treated at the time of established VOD. Given the poor results seen in treating late VOD, we suggest that early treatment with tPA may improve the outcome in patients who develop signs of hepatotoxicity following marrow transplantation. Keywords: tissue plasminogen activator; hepatotoxicity; bone marrow transplant Hepatic veno-occlusive disease (VOD) is a frequent and serious complication of bone marrow transplantation (BMT). Published reports indicate an incidence of 5-50%, and a mortality as high as 15% depending on the clinical series and the definition used.
Summary:
The treatment of established veno-occlusive disease (VOD) of the liver with tissue plasminogen activator (tPA) has been disappointing. In attempts to improve upon these results we identified a subgroup of patients with consistently elevated bilirubin levels who did not meet conventional criteria for VOD (Susp VOD) but who had a significant risk of later developing clinical VOD. In January 1994 we began to treat patients who developed Susp VOD with tPA rather than waiting until they developed clinical VOD. We now report on the results of the first 37 patients who ultimately developed clinical VOD and received tPA therapy prior to Susp VOD, or at the time they had established VOD. Significant bleeding complications occurred in 13 (35%) patients but resolved with discontinuation of therapy in all but one. We found that patients treated early in the course of hepatotoxicity prior to the development of overt VOD had a significantly higher response rate and 100 day survival than patients treated at the time of established VOD. Given the poor results seen in treating late VOD, we suggest that early treatment with tPA may improve the outcome in patients who develop signs of hepatotoxicity following marrow transplantation. Keywords: tissue plasminogen activator; hepatotoxicity; bone marrow transplant Hepatic veno-occlusive disease (VOD) is a frequent and serious complication of bone marrow transplantation (BMT). Published reports indicate an incidence of 5-50%, and a mortality as high as 15% depending on the clinical series and the definition used. [1] [2] [3] [4] Clinically, VOD has been defined as hyperbilirubinemia within the first 4 weeks following BMT, with associated findings of ascites, unexplained weight gain, hepatomegaly or right upper quadrant pain. VOD is characterized histologically, by necrosis of zone 3 hepatocytes and deposition of fibrin and factor VIII in hepatic venules. These findings suggest a role of the coagulation system in the pathophysiology of VOD. sparse, and treatment options are limited. Despite the paucity of data, early experience with tissue plasminogen activator (tPA) is encouraging. Presently, tPA represents the most promising therapy for the treatment of hepatotoxicity following BMT. [6] [7] [8] [9] Based on the promising initial reports of Bearman et al, 9 we began to treat patients with established VOD with tPA in April 1993. Our early experience in treating patients with advanced VOD using tPA was unfavorable, as in the larger trial recently reported by Bearman and colleagues. 10 Others had suggested that successful treatment required early therapy. 11 Thus in January 1994 we began to treat patients when they developed persistent unexplained hyperbilirubinemia (suspected VOD) without additional clinical evidence of VOD. To investigate whether earlier treatment may influence the course of hepatotoxicity, we examined only those patients who developed clinical VOD, and compared the results for those who received tPA prior to or after developing clinical VOD. The modification consisted of increasing the threshold for unexplained weight gain to Ͼ10% of baseline, since in our experience many patients (with no other suggestion of hepatic toxicity) developed weight gains of 2-5% above base- Initially, due to concerns about the toxicity of tPA, only patients who met McD or J criteria were treated with tPA. Since January 1994 all patients who developed Susp VOD and did not have contraindications to tPA therapy, also began treatment with tPA prior to progressing to clinical VOD.
Methods

Patient selection and hepatotoxicity grading
Treatment
Tissue plasminogen activator was administered as a 4-h continuous intravenous infusion for a minimum of 2 days. Therapy continued until maximal clinical response (no continued improvement for 2 days or return to normal bilirubin) or until onset of complications which necessitated discontinuation. Most patients received a daily tPA dose of 30 mg. One patient received 40 mg for 1 day, with a subsequent decrease to 30 mg daily after the development of a hematoma. Two patients who progressed while receiving the 30 mg dose received 40 mg daily for 11 and 12 days, respectively. Patients were concomitantly treated with heparin sodium, 5 U/kg/h, as a continuous intravenous infusion. Attempts were made to maintain the platelet count above 50 000/l during tPA administration. Therapy was discontinued if major bleeding episodes developed.
Patients were monitored daily for the development of hepatomegaly, hepatic tenderness, weight gain, ascites or signs of bleeding. Serum bilirubin levels, platelet counts, prothrombin (PT) and partial thromboplastin (PTT) times were measured daily. If the PTT was found to be greater than 50 s, the test was repeated and the heparin dose was decreased by 50 U/h if the PTT remained elevated.
Response
Response to tPA was defined as resolution (normalization of bilirubin and symptoms), improvement (a decrease of more than 50% within 10 days of therapy) or no response. Responses were measured based on the initial bilirubin values when treatment began.
Group means were compared using the Fisher exact test.
Results
Two hundred and sixty patients underwent bone marrow transplantation (123 allogeneic, 137 autologous) at Roswell Park Cancer Institute between April 1993 and July 1996. During that period, 40 patients (15%) developed clinical VOD (see Table 1 ). VOD developed in 32 of the 123 patients (26%) who underwent allogeneic (allo) BMT, and in eight of the 137 patients (6%) who underwent autologous (auto) BMT. Thirty-seven of these patients were treated with tPA. The characteristics of these 37 patients are shown Table 3 shows the day post BMT when tPA therapy was initiated, the duration of tPA treatment, the bilirubin at initiation of tPA, the peak bilirubin within the first 30 days post BMT and the estimated risk for severe VOD based on Bearman's model 12 for patients who developed VOD. There were no statistically significant differences between the groups in the day of initiation, duration of therapy, the estimated risk of severe VOD or the median bilirubin when tPA was started. As would be expected, the peak bilirubin was higher in patients who progressed to more advanced stages of VOD. V = VP16; C = cyclophosphamide; T = TBI; Th = thiotepa; Cp = cisplatin; Bu = busulfan; B = BCNU.
tPA for hepatotoxicity following BMT J Schriber et al 1313 Table 3 Characteristics of patients receiving tPA therapy for hepatotoxicity post BMT Values are median (range).
Thirteen of 37 patients (35%) developed clinically significant bleeding while receiving tPA. Table 4 shows the types of bleeding complications, the grade of VOD at the time of bleeding, the duration of tPA therapy when the complication arose and the clinical outcome of the bleeding episode. The most common bleeding complication was diffuse alveolar hemorrhage, which occurred in five patients (13%). The median duration of tPA therapy at the time of bleeding was 7 days (range 1-21). One patient (3%) had a fatal retroperitoneal bleed, all other bleeding complications resolved when tPA was discontinued. In the 22 additional patients who received tPA for Susp VOD there were two with significant bleeding, both of whom resolved with discontinuation of tPA. No surgical interventions were required for any patient and there were no long-term sequelae of any bleeding complication. Two patients received blood transfusions due to bleeding complications (retroperitoneal and hematemesis). In the 12 evaluable patients who stopped tPA for bleeding complications, six had resolution of their hepatotoxicity, four had improved and two showed no response at the time of tPA discontinuation. All four who had demonstrated improvement worsened after discontinuation of tPA. Responses are shown in Table 5 stratified by the grade of hepatotoxicity when tPA was initiated. Hepatotoxicity resolved or improved in 16 of 24 (67%) patients who received tPA prior to the development of clinical VOD. In contrast hepatotoxicity improved in only three of 13 patients (23%) who were first treated after meeting McD or J criteria for VOD (P Ͻ 0.02).
The 100 day non-relapse survival of 42% was significantly higher in patients who received tPA prior to the development of clinical VOD compared to the 8% survival in patients first treated for established VOD (P Ͻ 0.03).
Discussion
Previous studies had suggested that tPA may be effective therapy in a high proportion of patients with established VOD. Bearman et al 10 recently reviewed their experience in 42 patients treated with tPA for established VOD. Twelve of the 42 (29%) responded to tPA therapy; this is similar to the response rate of 23% that we observed in patients receiving therapy at the time of established VOD. In their study, responses were not seen in patients with more advanced disease who required dialysis or mechanical ventilation prior to therapy. In contrast to their earlier report 9 a significant number of patients had bleeding (88%) and 10 had life-threatening hemorrhage.
The potential for fatal bleeding has also been seen by others. 11, 13 This has limited the use of tPA to only the more extreme cases of VOD and even then with some trepidation. Initially we began tPA therapy only for patients with established VOD. Unfortunately, we did not observe Table 5 Response to tPA vs time of initiation of tPA tPA for hepatotoxicity following BMT J Schriber et al the dramatic clinical improvements described by other investigators. [6] [7] [8] [9] However, neither did we encounter irreversible major bleeding in these patients.
We hypothesized that tPA would be more effective if used earlier in the course of the disease. We reasoned that if VOD is caused in part by activation of the coagulation system, initiation of therapy prior to the onset of hepatic fibrosis might be more effective in reducing the associated mortality. A retrospective analysis of our BMT patients had identified a subset with persistent unexplained hyperbilirubinemia who did not meet the criteria for clinical VOD. This group had a higher early mortality than patients without evidence of hepatotoxicity. We felt that these patients, whom we labeled as Suspected VOD (Susp) could potentially benefit from early tPA therapy rather than waiting until they met established criteria for clinical VOD.
We now demonstrate that patients who ultimately develop clinical VOD who had received tPA therapy early, not only have a significantly higher response rate but also a decreased mortality relative to patients first treated when they developed overt VOD. Since these patients differed only in the timing of their tPA therapy, it appears that the strategy of early identification of patients at high risk for progression and treatment prior to the onset of overt VOD was effective.
We were also struck by the relative safety of tPA therapy in this high risk setting. Although patients often had refractory thrombocytopenia and 20% were intubated, there was only one case of fatal bleeding (3%) associated with tPA therapy. Although hardly insignificant, since 13 patients (35%) required discontinuation of therapy, bleeding complications resolved in 12 of 13 and only two patients required red cell transfusions. This suggests that tPA at a dose of 30 mg/day is associated with acceptable morbidity and mortality post BMT even in intubated patients. Patients must be carefully monitored for bleeding, and therapy discontinued at the first sign of complications. The higher incidence and severity of bleeding observed by Bearman et al 10 may have been caused by either the higher dose of tPA they utilized or the difference in timing of therapy.
Our results suggest that treatment with tPA prior to the onset of clinical VOD increases response rates and decreases mortality in comparison to delayed initiation of therapy. However these data must be interpreted with caution. This was not a randomized trial comparing early vs late therapy and a strategy of early treatment for all patients with suspicious disease may result in overtreatment for some patients who might have a more benign course and thus expose them to unnecessary risks of bleeding. Given the low incidence of irreversible bleeding complications that we observed, we believe that a randomized trial to test this hypothesis is feasible.
